ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan (Q37317424)

From Wikidata
Jump to navigation Jump to search
scientific article published on 05 June 2009
edit
Language Label Description Also known as
English
ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan
scientific article published on 05 June 2009

    Statements

    ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan (English)
    Anne Hiukka
    Camilla Pettersson
    Malin Levin
    Martin Adiels
    Susanne Teneberg
    Eeva S Leinonen
    Kim Ekroos
    5 June 2009
    2018-2026

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit